Core Viewpoint - Lepu Medical (300003.SZ) has signed a strategic cooperation agreement with Hanhai Information Technology (Shanghai) Co., Ltd, aiming to establish a long-term and comprehensive partnership to develop the medical aesthetics business sector [1] Company Summary - The partnership will enable Hanhai Information to promote and operate the brands under Lepu Medical's medical aesthetics segment, providing both online and offline operational solutions [1] - This collaboration is expected to create new online sales channels for Lepu Medical's medical aesthetics segment, complementing existing offline sales channels and building an omnichannel sales network [1] Industry Summary - Hanhai Information is a core entity of Meituan in Shanghai, legally operating Meituan and Dianping, and possesses complete platform operational rights [1]

Group 1 - Company East China Pharmaceutical announced a joint investment of 2 billion yuan to establish a specialized pharmaceutical industry investment fund with Shanghai Fuguang Private Equity Fund and others [1] - The company will contribute 980 million yuan, accounting for 49% of the total investment, while the other partners will contribute 490 million yuan each, representing 24.5% [1] - The fund will focus on investing in innovative drugs, medical aesthetics, health, animal protection, and other related fields that align with Hangzhou's five major industrial ecosystems [1] Group 2 - For the first half of 2025, East China Pharmaceutical reported revenue of 21.675 billion yuan, a year-on-year increase of 3.39%, and a net profit attributable to shareholders of 1.815 billion yuan, up 7.01% [2] - The pharmaceutical industrial sector is the core business, but the medical aesthetics segment faced a 17.5% decline, generating revenue of 1.112 billion yuan [2] - Innovative drugs have become a key growth driver, with sales and agency service revenue reaching 1.084 billion yuan, a 59% increase, accounting for 14.8% of the pharmaceutical industrial revenue [2] Group 3 - The company increased its R&D expenditure by 33.75% to 1.484 billion yuan in the first half of the year, with direct R&D spending rising by 54.21% to 1.174 billion yuan [3] - Direct R&D spending accounted for 15.97% of the pharmaceutical industrial revenue [3]